Skip to main content

Cerebrolysin vs Dihexa

Both Cerebrolysin and Dihexa are used for cognitive and neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

Cerebrolysin

Evidence B

Cerebrolysin (porcine brain peptide complex)

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

View full Cerebrolysin profile →

Dihexa

Evidence C

Dihexa (PNB-0408)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

View full Dihexa profile →

Side-by-Side

AttributeCerebrolysinDihexa
Evidence GradeBC
FDA StatusNot FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementiaNot FDA-approved — research compound (HGF/c-Met-mimetic)
Typical DoseTrial range: 5–30 mL daily (intravenous infusion)8–45 mg orally daily (research-only)
Clinics Indexed4110
Categoriescognitive, neuroprotectioncognitive, neuroprotection

Key reported benefits — Cerebrolysin

  • Stroke recovery support
  • TBI rehabilitation
  • Cognitive function in dementia

Key reported benefits — Dihexa

  • Synaptogenesis (preclinical)
  • Memory improvement (animal)
  • Possible Alzheimer's relevance

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons